Chardan Capital maintains a buy rating on iBio

Brief Summary

Chardan Capital maintained its ‘Buy’ rating for iBio with an unchanged target price of $5.00.

Impact of The News

The event of Chardan Capital maintaining its ‘Buy’ rating for iBio is a company-specific event within the financial domain.

Impact Transmission Path:

• Company Level Impact:

• This rating affirmation might positively influence investor sentiment towards iBio, potentially stabilizing its stock price as the market perceives continued confidence from Chardan Capital.

• Maintaining the target price suggests that the analysts believe the company’s future prospects remain stable in line with previous expectations.

• Broader Industry Implications:

• Although specific to iBio, such reaffirmations can subtly influence peer companies within the same sector by reinforcing general market confidence in the biotechnology space.

Overall, the stability in rating and target price by Chardan Capital could help maintain or slightly boost investor confidence in iBio in the short term.